gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by Virometix

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): V-306

            Therapeutic Area: Infections and Infectious Diseases Product Name: V-306

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            All 20 subjects received the first dose of V-306 or placebo, as planned and early clinical experience is encouraging with no adverse events reported to date.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): V-306

            Therapeutic Area: Infections and Infectious Diseases Product Name: V-306

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing July 16, 2020

            Details:

            The financing will ensure the company can complete the phase 1 clinical trial of its lead asset V-306 in RSV, advance pre-clinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.